Hong Kong have suffered more rugby sevens heartbreak, surrendering a late lead to lose 24-19 to Canada in sudden-death extra time of their crunch HSBC SVNS 3 semi-final on Sunday. Head coach Jevon ...

FORT LAUDERDALE, Fla. — What’s the secret to winning a seven-a-side tournament when $2 million is on the line? “Be brave,” San Diego Wave midfielder Gia Corley said after her club won the second World ...

Andy is a seasoned technology journalist with more than 15 years experience in the mobile industry, writing for Digital Trends, Wired, and more. During that time he has reviewed hundreds of ...

Nearly a year to the day after unveiling its predecessor, Qualcomm is ready to debut its next AI-centric mid-range processor. While we’ll have to keep on waiting for an eventual Snapdragon 8 Elite 2 ...

Qualcomm has unveiled the Snapdragon 7s Gen 4, a 4nm chipset designed for mid-range smartphones. It offers up to 2.7GHz CPU speeds, improved features, and WFHD+ display support at 144Hz. The chip also ...

It’s widely recognized that the crises of loneliness, disconnection, and social fragmentation are touching nearly every aspect of our lives, from personal well-being to public health to democracy ...

Game 7 in the NBA Finals is the pinnacle of high-stakes basketball—a win-or-go-home battle for the championship. As of Sunday’s highly anticipated 2025 Game 7 finale between the Oklahoma City Thunder ...

BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying ...

Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that ...

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...